Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors.

NCT04913285 is registered in ClinicalTrials.gov with Pierre Fabre Medicament as lead sponsor.

NCT NCT04913285
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04913285 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors.
Lead sponsor
Pierre Fabre Medicament
Phase
Phase 1
Overall status
Recruiting
Start date
August 4, 2021
Completion date
March 30, 2029
Enrollment
400 (estimated)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, non-small cell lung cancer, solid tumor, adult